The tumor suppressor CYLD is a deubiquitinating enzyme that suppresses polyubiquitin-dependent signaling pathways, including the proinflammatory and cell growth–promoting NF-κB pathway. Missense mutations in the CYLD gene are present in individuals with syndromes such as multiple familial trichoepithelioma (MFT), but the pathogenic roles of these mutations remain unclear. Recent studies have shown that CYLD interacts with a RING finger domain protein, mind bomb homologue 2 (MIB2), in the regulation of NOTCH signaling. However, whether MIB2 is an E3 ubiquitin ligase that acts on CYLD is unknown. Here, using the cell-free–based AlphaScreen and pulldown assays to detect protein–protein interactions, along with immunofluorescence assays and murine Mib2 knockout cells and animals, we demonstrate that MIB2 promotes proteasomal degradation of CYLD and enhances NF-κB signaling. Of note, arthritic inflammation was suppressed in Mib2-deficient mice. We further observed that the ankyrin repeat in MIB2 interacts with the third CAP domain in CYLD and that MIB2 catalyzes Lys-48–linked polyubiquitination of CYLD at Lys-338 and Lys-530. MIB2-dependent CYLD degradation activated NF-κB signaling via tumor necrosis factor alpha (TNFα) stimulation and the linear ubiquitination assembly complex (LUBAC). Mib2-knockout mice had reduced serum interleukin-6 (IL-6) and exhibited suppressed inflammatory responses in the K/BxN serum-transfer arthritis model. Interestingly, MIB2 significantly enhanced the degradation of a CYLDP904L variant identified in an individual with MFT, although the molecular pathogenesis of the disease was not clarified here. Together, these results suggest that MIB2 enhances NF-κB signaling in inflammation by promoting the ubiquitin-dependent degradation of CYLD.

NF-κB is a transcription factor complex that regulates the expression of various human genes involved in numerous important biological processes, including inflammatory and immune responses, proliferation, and cell development (1, 2). Activation of NF-κB occurs in response to various signals, including cytokines, injury, viral infection, and stress. Inappropriate activation of the NF-κB signaling pathway promotes autoimmune diseases, chronic inflammation, and various cancers (3–7). Under basal conditions, NF-κB is maintained in an inactive form as a result of its interaction with the inhibitory protein, IκB. Activation of the NF-κB signaling pathway is typically initiated by extracellular stimuli. These stimuli are recognized by cell surface receptors and are transmitted into the cell through the use of adaptor signaling proteins, which initiate a signaling cascade. The signaling cascade culminates in the phosphorylation of IκB kinase (IKK) after the upstream factors of IKKγ/NEMO and RIP1 are ubiquitinated. Activated IKK then phosphorylates the IκB subunit of the NF-κB–IκB complex in the cytoplasm. After the phosphorylated IκB is ubiquitinated and degraded by proteasome, the NF-κB proteins are released and the free NF-κB dimer is then transported into the nucleus and induces the expression of its target genes (8, 9). Ubiquitination is therefore an important regulatory mechanism in the NF-κB signaling cascade.

Ubiquitination is a posttranslational modification of proteins that forms a part of the energy-dependent protein degradation mechanism that acts via the proteasome. It is known to be
involved in the control of various kinds of biological phenomena, including the cell cycle, signal transduction, and transcriptional regulation (10, 11). Ubiquitin consists of 76 amino acids and contains a posttranslational modification site where it is attached to a substrate protein. Ubiquitination is carried out in three steps, activation, conjugation, and ligation, performed by ubiquitin-activating enzymes (E1), ubiquitin-conjugation enzymes (E2), and ubiquitin ligases (E3), respectively (10, 11). Recent studies have shown that the type of ubiquitin linkage formed determines the subsequent biological effect of the ubiquitination event (12). In particular, it has been shown that a Lys-48–linked polyubiquitin chain is involved in degradation by the proteasome, whereas a Lys-63–linked and Met-1–linked linear polyubiquitin chains are involved in the regulation of signal transduction such as NF-κB activation pathway (13–15).

In addition, these polyubiquitin chains are deconjugated by specific deubiquitinating enzymes (DUBs), suggesting that linkage-dependent signaling is a reversible response (16). Cylindromatosis (CYLD), having DUB activity, is a tumor suppressor that plays a key role in proliferation and cell death (17). CYLD was originally identified as a gene that is mutated in familial cylindromatosis, a genetic mutation that causes the development of cancerous skin appendages, called cylindromas (17). Mutations in the CYLD gene are found in individuals with numerous syndromes, including Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma (MFT), which are all characterized as having a variety of skin appendage neoplasms (18). At least nine missense mutations in CYLD have been found in these diseases. The nonsense mutations are known to cause disease as a result of CYLD deficiency, however, the role of the missense mutations remains unclear. Moreover, down-regulation of CYLD occurs in various types of human cancers, including melanoma and colon and lung cancers, in promoting tumorigenesis (17, 19–22).

CYLD has important roles in the regulation of NF-κB signaling (17). CYLD negatively regulates the NF-κB signaling pathway by removing Lys-63–linked and linear polyubiquitin chains from NEMO and RIP1 (23, 24). The function of the CYLD protein is itself regulated by posttranslational modification. In particular, a reduction in CYLD protein levels by ubiquitination leads to constitutive NF-κB activation (12). In particular, it has been shown that a Lys-48–linked polyubiquitin chain is involved in degradation by the proteasome, whereas a Lys-63–linked and Met-1–linked linear polyubiquitin chains are involved in the regulation of signal transduction such as NF-κB activation pathway (13–15). Consequently, mutations of CYLD significantly enhance degradation of the missense CYLD variant found in multiple familial trichoepitheliomas.

Results

MIB2 interacts with CYLD

A recent report showed the interaction between MIB2 and CYLD using co-immunoprecipitation from cell extracts (26). To confirm this interaction in vitro, we used the wheat cell–free–based AlphaScreen method as the protein–protein interaction detection system, as we have reported recently (29). NEMO protein is well-known to be an interaction partner of CYLD (30), and for this reason we used it as a positive control for this experiment. As expected, in the AlphaScreen assay, NEMO interacted with CYLD (see the middle bar in Fig. 1A). Importantly, MIB2 also interacted with CYLD, producing a very similar signal to that seen with NEMO (right-hand bar), indicating that MIB2 interacts with CYLD in vitro. To confirm this interaction, we also performed a GST-pulldown experiment using a GST-CYLD fusion protein and MIB2. Similar to the data in Fig. 1A, MIB2 was shown to interact with GST-CYLD (Fig. 1B), indicating that CYLD forms a distinct complex with MIB2. Next, to confirm this interaction in cells, we used the AGIA-tag system because it is a highly sensitive tag based on a rabbit mAb (31). AGIA-tagged CYLD was transfected into HEK293T cells with WT MIB2 or a catalytically inactive form (Mut). Both WT and Mut-MIB2 proteins were co-immunoprecipitated with AGIA-CYLD protein (Fig. 1C), suggesting that MIB2 interacts with CYLD in cells. Furthermore, we also observed that endogenous MIB2 could interact with endogenous CYLD in HEK293T cells by immunoprecipitation using an anti-MIB2 antibody (Fig. 1D). Taken together, these data suggest that MIB2 directly interacts with CYLD in cells.

CYLD contains three CAP domains and a catalytic domain (Fig. 1E). To identify the region in CYLD that interacts with MIB2, we generated five deletion mutants of CYLD and expressed them as N-terminally FLAG-tagged proteins. All of the recombinant CYLD mutant proteins and the MIB2 protein were produced using the cell-free system and the protein–protein interactions were analyzed using an AlphaScreen similar to the experiment described in Fig. 1A. The data indicated that three mutants, namely D3 (Δ287–589), D4 (Δ287–488), and B (Δ489–532) had reduced binding compared with the other two deletion mutants, D1 (1–589) and D2 (286–589) (Fig. 1F). To confirm the identification of the CYLD region that bound to MIB2 in cells, full-length CYLD and the two D1 and D3 mutants were overexpressed in cells. Immunoprecipitation using an anti-MIB2 antibody showed that the D3 mutant could not be co-immunoprecipitated with MIB2, whereas full-length CYLD and the D1 mutant were co-immunoprecipitated (Fig. 1G), suggesting that MIB2 principally interacts with the third CAP domain (amino acids 287–589) in the central region of CYLD.

MIB2 has five conserved domains, two MIB/Herc domains, an ankyrin repeat domain, and two RING domains (Fig. 1H). To identify the region in MIB2 that interacts with CYLD, we generated three deletion mutants of MIB2. An in vitro AlphaScreen assay (Fig. 1I) and a cell-based assay (Fig. 1J) revealed that CYLD interacts with the ankyrin repeat region of MIB2. Next, we examined the cellular localization of both CYLD and MIB2 by immunofluorescence. The data...
revealed that both CYLD and MIB2 were co-localized in the cytoplasm (Fig. S1A). Interestingly, the RING domains-deleted mutant of MIB2 (MIB2ΔRING) was not localized in the cytoplasm, but instead was found to be localized in the nucleus (Fig. S1B). Therefore the interaction between CYLD and MIB2ΔRING could not be confirmed in the cells. Taken together, these results indicated that MIB2 interacts with CYLD both in vitro and in cells.

Figure 1. MIB2 interacts with CYLD. A, determination of CYLD-MIB2 interaction by AlphaScreen. FLAG-CYLD and biotinylated DHFR, NEMO, or MIB2 were synthesized by using a wheat cell-free system, and their interactions were analyzed by AlphaScreen. Mean ± S.E. (n = 4). Statistical significance was assessed using one-way ANOVA. *, p < 0.01. B, determination of CYLD-MIB2 interaction by pulldown assay. GST pulldown assay was carried out using control GST or GST-CYLD fusion proteins on Sepharose beads followed by incubation with MIB2. C, analysis of CYLD-MIB2 interaction in cells. Immunoprecipitation using an anti-AGIA antibody was performed from extracts of HEK293T cells transfected with V5-tagged MIB2 and AGIA-tagged CYLD. The presence of MIB2 in the immunoprecipitate was evaluated by immunoblotting with the respective antibody. The MIB2 mutant (Mut) used contained a CS mutation in the two RING domains. D, determination of endogenous CYLD-MIB2 interaction. Immunoprecipitation using either control IgG or anti-MIB2 antibody was performed from HEK293T cell extracts. The endogenous interaction of MIB2 with CYLD was evaluated by immunoblotting with an anti-CYLD antibody. E, schematic representation of full-length CYLD (FL), along with its various deletion mutants (D1–D5). F, identification of CYLD-binding region in vitro. The AlphaScreen analysis was performed between CYLD and MIB2 or its deletion mutants. Biotinylated MIB2, or FLAG-CYLD FL and its various deletion mutants, were synthesized by using wheat cell-free system, and then were used. G, identification of CYLD-binding region in cell. HEK293T cells expressing endogenous MIB2 were transfected with the indicated FLAG-tagged CYLD constructs and the interaction between CYLD and MIB2 was determined by immunoprecipitation and immunoblotting with the indicated antibodies. H, schematic representation of full-length CYLD (FL), along with its various deletion mutants (D1–D3). I, identification of MIB2-binding region in vitro. The AlphaScreen signals between CYLD and MIB2 or its deletion mutants. Biotinylated CYLD or FLAG-MIB2 FL and its various deletion mutants were used. J, identification of MIB2-binding region in cell. HEK293T cells expressing endogenous CYLD were transfected with the indicated V5-tagged MIB2 constructs, and the interaction between CYLD and MIB2 was determined by immunoprecipitation and immunoblotting with the indicated antibodies.
MIB2 enhances inflammation by degradation of CYLD

MIB2 possesses RING-type E3 ligase activity (26, 28), and a recent study has shown that MIB2 enhances NF-κB activation by its auto-ubiquitination through Lys-63–linked ubiquitination with a nondegradative polyubiquitin chain (28). In addition, CYLD has been shown to be a negative regulator of NF-κB signaling (23, 30). From these two lines of evidence, we considered the possibility that MIB2 ubiquinates CYLD through Lys-48–linked ubiquitination with a degradative polyubiquitin chain, but not through the Lys-63–linked ubiquitination. We therefore assessed whether MIB2 could directly ubiquinate CYLD using an in vitro ubiquitination assay with purified recombinant GST-CYLD and WT MIB2 (MIB2 WT) and catalytically inactive MIB2 (MIB2 Mut) in various combinations as indicated. B, identification of RING domains of MIB2 indispensable for CYLD ubiquitination. In vitro ubiquitination assay was performed using recombinant HA-tagged WT MIB2 (MIB2 WT), a MIB2 RING1 mutant (Mut1), a MIB2 RING2 mutant (Mut2), and a RING1/RING2 double mutant of MIB2 (Mut1, 2) in various combinations as indicated. C, analysis of CYLD ubiquitination by MIB2 in cell. MIB2 was expressed in HEK293T cells along with HA-ubiquitin. Ubiquitination of the endogenous CYLD was evaluated by immunoprecipitation of CYLD using an anti-CYLD antibody followed by anti-HA immunoblotting. Vector: mock pcDNA3.2, Mut: catalytically inactive form. D, determination of the type of polyubiquitination chain of MIB2 for CYLD ubiquitination using specific antibody. V5-tagged WT or catalytically inactive MIB2 (Mut) was expressed in HEK293T cells along with HA-tagged WT ubiquitin (Ub). Cells were treated with MG132 (10 μM) for 6 h and the level of CYLD ubiquitination was evaluated by immunoprecipitation of CYLD using an anti-CYLD antibody followed by immunoblotting with anti-HA, anti–Lys-48 (K48) Ub, or anti–Lys-63 (K63) Ub antibodies. E, identification of CYLD-ubiquitination site by MIB2. WT MIB2 was expressed in HEK293T cells along with HA-ubiquitin and either WT CYLD or three CYLD mutants (K338R, K530R, and K338/530R). Ubiquitination of the overexpressed CYLD was evaluated by immunoprecipitation of CYLD using an anti-FLAG antibody followed by anti-HA immunoblotting.

Figure 2. MIB2 ubiquinates CYLD via Lys-48–linked polyubiquitin chain. A, analysis of CYLD ubiquitination by MIB2 in vitro. In vitro ubiquitination assay was performed using recombinant GST-CYLD as a substrate in the presence of FLAG-tagged ubiquitin, E1 (UBE1), E2 (UbcH5B), recombinant His-tagged WT MIB2 (MIB2 WT) and catalytically inactive MIB2 (MIB2 Mut) in various combinations as indicated. B, identification of RING domains of MIB2 indispensable for CYLD ubiquitination. In vitro ubiquitination assay was performed using recombinant HA-tagged WT MIB2 (MIB2 WT), a MIB2 RING1 mutant (Mut1), a MIB2 RING2 mutant (Mut2), and a RING1/RING2 double mutant of MIB2 (Mut1, 2) in various combinations as indicated. C, analysis of CYLD ubiquitination by MIB2 in cell. MIB2 was expressed in HEK293T cells along with HA-ubiquitin. Ubiquitination of the endogenous CYLD was evaluated by immunoprecipitation of CYLD using an anti-CYLD antibody followed by anti-HA immunoblotting. Vector: mock pcDNA3.2, Mut: catalytically inactive form. D, determination of the type of polyubiquitination chain of MIB2 for CYLD ubiquitination using specific antibody. V5-tagged WT or catalytically inactive MIB2 (Mut) was expressed in HEK293T cells along with HA-tagged WT ubiquitin (Ub). Cells were treated with MG132 (10 μM) for 6 h and the level of CYLD ubiquitination was evaluated by immunoprecipitation of CYLD using an anti-CYLD antibody followed by immunoblotting with anti-HA, anti–Lys-48 (K48) Ub, or anti–Lys-63 (K63) Ub antibodies. E, identification of the type of polyubiquitination chain of MIB2 for CYLD ubiquitination using ubiquitin mutants. FLAG-tagged CYLD was co-transfected with either control, WT MIB2, or catalytically inactive MIB2 (Mut), along with either HA-tagged WT, Lys-48, or Lys-63 ubiquitin (Ub). Cells were treated with MG132 (10 μM) for 6 h and the level of CYLD ubiquitination was evaluated by immunoprecipitation of CYLD using an anti-CYLD antibody, followed by anti-HA immunoblotting. F, identification of CYLD-ubiquitination site by MIB2. WT MIB2 was expressed in HEK293T cells along with HA-ubiquitin and either WT CYLD or three CYLD mutants (K338R, K530R, and K338/530R). Ubiquitination of the overexpressed CYLD was evaluated by immunoprecipitation of CYLD using an anti-FLAG antibody followed by anti-HA immunoblotting.
Mut2 being the first and second RING CS mutants, respectively. Both Mut1 and Mut2 had a lower level of ubiquitination of CYLD compared with WT MIB2, although the double mutant (Mut1, 2) completely lacked ubiquitination activity (Fig. 2B), suggesting that both of the RING domains in MIB2 function in the ubiquitination of CYLD.

Next, we attempted to confirm ubiquitination in cultured cells. HEK293T cells were transiently transfected with FLAG-tagged CYLD and either V5-tagged WT MIB2 or a catalytically inactive MIB2 (containing a CS mutation in both RING domains) along with HA-tagged ubiquitin. Following immunoprecipitation with anti-CYLD antibody and immunoblotting by anti-HA antibody, we detected significant ubiquitination of CYLD when it was co-expressed with WT MIB2, but not with the catalytically inactive mutant (Fig. 2C, IB: HA). In order to identify the type of polyubiquitin chain conjugated to CYLD by MIB2, we used specific antibodies, which are capable of detecting either Lys-48— or Lys-63—linked polyubiquitin, as well as ubiquitin mutants lacking the ubiquitination sites except for Lys-48 or Lys-63. Ubiquitination of CYLD was detected using the specific antibody against Lys-48—linked polyubiquitin (IB: Lys-48 panel in Fig. 2D), whereas it was not found using the anti—Lys-63 polyubiquitin antibody (IB: Lys-63 panel). In the same manner, a cell-based ubiquitination assay using HA-tagged single lysine ubiquitin mutants at Lys-48 or Lys-63 clearly showed that ubiquitination of CYLD was detected using Lys-48—ubiquitin (HA-Ub Lys-48), but not Lys-63—ubiquitin (HA-Ub Lys-63) (Fig. 2E). Taken together, these data indicate that MIB2 mediates Lys-48—linked polyubiquitination of CYLD.

To identify a ubiquitination site(s) on CYLD, a LC-MS/MS analysis was performed on K-ε-GG antibody immunoprecipitates of MIB2-ubiquitinated CYLD. This MS analysis showed that Lys-338 and Lys-530 in CYLD were ubiquitinated (Fig. S2). To confirm these findings, we constructed three mutants of CYLD lacking these ubiquitination sites namely K338R, K530R, and the double mutant K338/530R and transfected them into cells. As a result, CYLD containing the double mutation was not ubiquitinated, whereas the single mutants were ubiquitinated by MIB2 (Fig. 2F). These data indicate that MIB2-dependent ubiquitination of CYLD occurs at both Lys-338 and Lys-530. Interestingly, these two ubiquitination sites are located in the MIB2 interaction domain (287–589) (Fig. 1, E–G) and have been highly conserved among the CYLD orthologs (Fig. S3), suggesting that CYLD may be regulated by MIB2 through the ubiquitination of these lysines in many species.

MIB2 regulates CYLD protein stability through polyubiquitination

Next, we investigated whether the Lys-48—linked polyubiquitination of CYLD by MIB2 induces CYLD degradation. The endogenous CYLD protein in HeLa cells endogenously expressing the MIB2 protein was stabilized by treatment with the proteasome inhibitor MG132 (Fig. 3A), suggesting that CYLD is degraded by the 26S proteasome. To test whether the destabilization of CYLD depends on MIB2, we established stable cell lines constitutively expressing MIB2 or GFP. As a result, the level of the endogenous CYLD protein decreased following constitutive expression of MIB2 compared with that of the negative control (GFP) (Fig. 3B). Furthermore, HeLa cells were transiently co-transfected with CYLD and either V5-tagged WT MIB2 or the catalytically inactive MIB2 mutant (containing CS mutations, Mut1,2, in both RING domains). Co-expression of CYLD and MIB2 WT resulted in a remarkable decrease in the level of CYLD, whereas no decrease in CYLD was seen in the presence of the catalytically inactive MIB2 mutant (Fig. 3C). This MIB2-dependent decrease in CYLD was completely recovered following treatment of the cells with MG132 (Fig. 3D), suggesting that MIB2-dependent ubiquitination of CYLD induces its degradation by the proteasome.

To test whether the expression level of endogenous MIB2 affects the stability of CYLD, two MIB2-specific siRNAs were used to repress MIB2 expression in cells. Both MIB2-specific siRNAs dramatically increased the level of CYLD protein compared with the negative control (Fig. 3E). To confirm this result, an MIB2 siRNA-resistant gene was designed and was transiently transfected in HeLa cells. The data showed that the expression of CYLD was dramatically decreased following expression of the siRNA-resistant MIB2 gene (Fig. 3F), although there was no change in cells expressing MIB2 mutant compared with the control, suggesting that MIB2 expression decreases the levels of CYLD. Furthermore, using a cycloheximide chase experiment, co-expression with CYLD of V5-tagged WT MIB2, but not the catalytically inactive MIB2, led to a decrease in the half-life of the CYLD protein (Fig. 3G). We also examined the half-life of the CYLD-K338/530R mutant that lacks the two ubiquitination sites using the same cycloheximide chase experiment. The data revealed that the ubiquitination mutant was stabilized even though MIB2 was overexpressed in the cells (Fig. 3H), suggesting that the CYLD destabilization depends on ubiquitination by MIB2. Taken together, these results indicate that MIB2 decreases the stability of CYLD in cells. A recent study has shown that that β-TRCP from the SCF (Skp-Cullin1-F-box protein) complex (SCFβ-TRCP), known to be a cullin-based E3 ligase, degrades CYLD by ubiquitination and promotes osteoclast differentiation (32). Therefore, we examined whether CYLD degradation by MIB2 is related to the activity of β-TRCP. Knockdown of the β-TRCP protein had no effect on MIB2-dependent CYLD destabilization (Fig. S4), suggesting that MIB2 degrades CYLD in a β-TRCP-independent manner.

MIB2 enhances NF-κB signaling

A recent study has reported that MIB2 is required for the Bcl10-dependent activation of NF-κB (28). In addition, CYLD has been reported to be involved in the canonical NF-κB signaling pathway (33). We therefore tested whether the expression of MIB2 affects NF-κB signaling. To investigate this, we used a reporter gene containing luciferase under the control of the NF-κB-promoter. Overexpression of MIB2 enhanced NF-κB activation compared with the empty vector as a negative control (Fig. 4A). Furthermore, overexpression of MIB2 in LUBAC- or TNFα-stimulated cells also enhanced NF-κB activation (Fig. 4B). Next, to confirm whether this MIB2-depen-
**MIB2 enhances inflammation by degradation of CYLD**

**Figure 3. MIB2 regulates CYLD protein stability by polyubiquitination.**

A, analysis of CYLD expression level by MG132 treatment. Protein expression levels of CYLD and MIB2 were analyzed in MG132-treated HeLa cells. B, analysis of CYLD expression level by constitutively overexpressed MIB2. HeLa cells stably expressing GFP or MIB2 were analyzed for the expression levels of CYLD and MIB2 by immunoblotting with their respective antibodies. C, determination of CYLD protein levels by overexpressed MIB2. CYLD were transiently transfected with plasmids encoding either V5-tagged WT MIB2 (WT) or a catalytically inactive mutant MIB2 (Mut) in HeLa cells. The expression level of CYLD was determined by immunoblotting with an anti-CYLD antibody. D, determination of CYLD protein levels by overexpressed MIB2 in MG132-treated cells. V5-tagged WT or Mut MIB2 was expressed in HeLa cells along with CYLD. Cell lysates were prepared after 6 h with 10 μM MG132 and analyzed by immunoblotting using an anti-CYLD antibody. E, analysis of CYLD expression level by MIB2 knockdown. HeLa cells stably expressing a control shRNA or one of two MIB2 shRNAs were analyzed for their expression of CYLD and MIB2 by immunoblotting with their respective antibodies. These quantified data were statistically analyzed and shown as a bar graph. Mean ± S.E.M. (n = 3). Statistical significance was assessed using one-way ANOVA. *, p < 0.05. F, analysis of CYLD stabilization depending on the MIB2 in MIB2 knockdown cells. After transfection with a control or a MIB2 siRNA, HeLa cells transiently expressing CYLD were transfected with plasmids encoding V5-tagged WT MIB2 or siRNA-resistant mutant. G, stabilization of CYLD protein by MIB2. HeLa cells transiently expressing CYLD were transfected with plasmids encoding V5-tagged WT MIB2 (MIB2 WT) or a catalytically inactive mutant (MIB2 Mut). After 22 h of transfection, the cells were treated with CHX and harvested at the indicated times. The expression levels of CYLD were determined by anti-CYLD immunoblotting. As control, mock pcDNA3.2 was transfected. These quantified data were statistically analyzed and shown as a bar graph. Mean ± S.E.M. (n = 3). Statistical significance was assessed using one-way ANOVA. *, p < 0.05; **, p < 0.01. H, role of MIB2-mediated ubiquitination sites of CYLD on its stability. HeLa cells transiently expressing V5-tagged WT MIB2 were transfected with plasmids encoding WT CYLD or CYLD-K338/530R mutant. After 22 h of transfection, cells were treated with CHX and harvested at the indicated times.
Figure 4. MIB2 enhances NF-κB signaling. A, analysis of NF-κB activity by overexpressed MIB2 under basal conditions. HEK293T cells were transfected with either WT MIB2 (WT), or a catalytically inactive MIB2 (Mut), along with a luciferase reporter containing the NF-κB promoter. Data from each luciferase assay shown are derived from three independent experiments. B, analysis of NF-κB activity by overexpressed MIB2 in HEK293T cells stimulated by TNFα and LUBAC. In LUBAC stimulation, NF-κB promoter activities were measured in HEK293T cells transfected with either WT or Mut MIB2, along with HOIP/HOIL-1L. In TNFα stimulation, the NF-κB promoter activities in HEK293T cells transfected with either WT or Mut MIB2 were measured following stimulation with TNFα for 4 h. C, analysis of NF-κB activity by co-expressed CYLD and MIB2. The NF-κB promoter activities were measured in HEK293T cells transfected with either WT or Mut MIB2, along with CYLD and HOIP/HOIL-1L. D, analysis of NF-κB activity in Mib2-deficient MEF cell. The NF-κB promoter activities induced by TNFα or LUBAC stimulation were measured in WT or Mib2-deficient MEF cells (KO). MIB2-V5 indicates transfection of human MIB2. Cells were treated with TNFα for 4 h or transfected with HOIP/HOIL-1L for TNFα or LUBAC stimulation, respectively. A, mean ± S.E. (n = 4); B–D, mean ± S.E. (n = 3). Statistical significance was assessed using one-way ANOVA. *, p < 0.05; **, p < 0.01; ***, p < 0.001. E, analysis of phosphorylated NF-κB proteins in Mib2-deficient MEF cell. Nuclear p65 was extracted from either WT (Mib2-WT) or Mib2-deficient (Mib2-KO) MEF cells. G, quantitative PCR analyses of NF-κB target genes in HeLa cells. After cells were transiently transfected with a control siRNA or one of two Mib2-targeted siRNAs they were treated with TNFα for the indicated times before quantitative PCR analysis. Mean ± S.E. (n = 3). Statistical significance was assessed using one-way ANOVA. *, p < 0.05 versus control.

MIB2 enhances inflammation by degradation of CYLD

dient NF-κB activation depended on CYLD, CYLD was co-transfected with MIB2, and the effect on NF-κB–driven luciferase activity was examined. Although the expression of CYLD alone inhibited LUBAC-stimulated NF-κB activation, co-transfection of CYLD with MIB2 rescued the NF-κB activity (Fig. 4C). Moreover, we investigated whether knock-out of MIB2 affects NF-κB activation. To analyze the effect of MIB2, Mib2-deficient mouse embryonic fibroblast (MEF) cells were isolated from homozygous Mib2 KO embryos. As expected, Mib2 expression levels in these cells were consistent with genotype (Fig. S5). NF-κB activity was decreased in both LUBAC- and TNFα-stimulated MEF cells (Fig. 4D). We also investigated whether proteins in the NF-κB pathway were affected by Mib2 knockout using MEFs. In TNFα-stimulated Mib2-deficient MEFs, the phosphorylation of both IkBα and p105 were remarkably decreased compared with TNFα-stimulated WT MEFs. Furthermore, the activation of extracellular signal-regulated kinase and c-Jun N-terminal kinase were also suppressed in a similar fashion in these Mib2-deficient MEFs (Fig. 4E). The appearance of p65 (RelA) in the nucleus following TNFα stimulation was also dramatically attenuated in these Mib2-deficient MEFs (Fig. 4F). MIB2 knockdown in HeLa cells also decreased the mRNA levels of several NF-κB target genes including NFKBIA (IkBα), TNFAIP3, and IL-8 (Fig. 4G). Taken together, these results suggest that MIB2-dependent CYLD degradation induces constitutive activation of the NF-κB signaling pathway. Interestingly, although the inactive form of MIB2 did not stimulate the activation of the NF-κB reporter following its co-expression with CYLD (Fig. 4C), its overexpression alone induced NF-κB activation (Fig. 4, A and B). These results suggest that the MIB2-CYLD interaction inhibits NF-κB activation when CYLD expression is low.
Mib2-KO mice showed suppression of the inflammatory response in the K/BxN serum-transfer arthritis model

As shown in Fig. 4, MIB2 enhances NF-κB signaling by inducing the degradation of CYLD. Next, we investigated the phenotype of Mib2-deficient mice under conditions of chronic inflammation, because constitutive NF-κB signaling is known to drive inflammation (34). The K/BxN arthritis model is known to share many features in common with human rheumatoid arthritis. In addition, the K/BxN serum-transfer arthritis (STA) model is a murine model in which rheumatoid arthritis, as well as other arthritic conditions, are known to occur (35). Accordingly, we investigated inflammation in the Mib2-KO mice using the K/BxN STA model. Mice were injected twice with K/BxN serum on day 0 and day 2, after which ankle thickness in the mice was measured over a period of 10 days. As a result, compared with Mib2-WT mice, Mib2-KO mice had a remarkable suppression of the inflammatory arthritis induced by the K/BxN serum transfer, as evidenced by the reduced ankle thickness (Fig. 5A). We also evaluated and scored the inflammation using a scale from 0 to 4 (36). In keeping with the ankle thickness data, the Mib2-KO mice showed a significantly lower clinical score compared with WT mice (Fig. 5, D and E). These in vivo data therefore suggest that MIB2 plays a role as an enhancer of inflammation driven by NF-κB signaling.

Unfortunately, commercially available anti-CYLD antibodies could not detect mouse Cyld protein in the tissues of Mib2-KO mice.

The CYLDP904L mutation found in MFT is predominantly degraded in a MIB2-dependent manner

Several reports have indicated that germline mutations in CYLD are related to Brooke-Spiegler syndrome, familial cylindromatosis, and MFT (18). Currently, 19 nonsense and 9 missense mutations in CYLD have been found in these diseases (Fig. S6). Although the nonsense mutations cause disease as a result of CYLD deficiency, the role of these missense mutations in disease remains unclear. We therefore investigated whether these mutations affect the MIB2-dependent degradation of CYLD. The missense mutants were introduced into FLAG-tagged CYLD and expressed in HeLa cells, with and without MG132 (Fig. 6A). As a result of this analysis, G896A and P904L were found to be stabilized by MG132 treatment, suggesting these two mutants are degraded by the proteasome. Next, we analyzed the degradation of all the FLAG-tagged CYLD missense mutants following co-expression in HEK293T cells. As a result, the degradation of two mutants, namely V654E and P904L, were significantly enhanced by MIB2 co-expression (Fig. 6B). From these two experiments, we focused on the P904L mutant. Surprisingly, the interaction between MIB2 and CYLDP904L was increased compared with WT CYLD using the AlphaScreen system (Fig. 6C). Furthermore, the MIB2-depen-
dent ubiquitination of CYLD<sup>P904L</sup> was dramatically enhanced in cells (Fig. 6D), and the protein stability of the CYLD<sup>P904L</sup> variant was dramatically decreased (Fig. 6E). Following TNFα treatment, NF-κB activation was enhanced following the co-expression of MIB2 and CYLD<sup>P904L</sup> (Fig. 6F), suggesting the efficient degradation of CYLD<sup>P904L</sup> by MIB2 than that of normal one. Taken together, these results suggest that the CYLD<sup>P904L</sup> mutation in MFT is predominantly degraded in an MIB2-dependent manner.

**Discussion**

In this study, we found that a deubiquitinating enzyme CYLD is degraded through ubiquitination by an E3 ubiquitin ligase MIB2. Because many signal transduction pathways are modulated by E3 ligase-dependent ubiquitination, the deubiquitination performed by DUB is a key regulator of these signaling pathways (37–41). The main enzymatic function of CYLD is to deubiquitinate two types of polyubiquitination chains, referred to as Lys-63– and linear-linked chains. These two polyubiquitin chains are found in the components of various important signaling cascades, including the NF-κB pathway, the antiviral response, and the mitogen-activated protein kinase pathway, and interestingly CYLD has been shown to be involved in the regulation of these pathways (25, 42, 43). On the other hand, it has been reported that MIB2 enhances the NF-κB pathway on Bcl3-dependent antiviral response signaling pathway by ubiquitinating TANK-binding kinase 1 (TBK1) through a Lys-63–linked polyubiquitin chain (28, 44).

**Figure 6.** MIB2-mediated enhanced degradation of CYLD is involved in a pathogenesis of trichoepithelioma. A, analysis of expression levels of CYLD mutants in MG132-treated cells. HeLa cells were transfected with either WT FLAG-tagged CYLD or the indicated FLAG-tagged CYLD mutants, and the CYLD expression levels were analyzed by immunoblotting with an anti-FLAG antibody in cells treated with or without MG132. B, analysis of expression levels of CYLD mutants by overexpressed MIB2. HeLa cells transiently expressed either WT FLAG-tagged CYLD or the indicated FLAG-tagged CYLD mutants were transfected in the presence or absence of V5-tagged WT MIB2. The expression levels of the CYLD proteins were determined by anti-FLAG immunoblotting. C, determination of interaction between CYLD-P904L mutant and MIB2 by AlphaScreen. Interactions between biotinylated MIB2 (Bio-MIB2) and either FLAG-tagged WT CYLD or CYLD-P904L mutant were analyzed by AlphaScreen. D, analysis of ubiquitination of CYLD-P904L mutant by MIB2 in cell. The ubiquitination of overexpressed CYLD was evaluated by immunoprecipitation of CYLD using an anti-FLAG antibody followed by anti-HA immunoblotting. E, destabilization of CYLD-P904L mutant by MIB2. HeLa cells transiently expressing MIB2 were transfected with plasmids encoding either FLAG-tagged WT MIB2 or the P904L mutant. After 20 h of transfection, cells were treated with CHX and harvested at the indicated times. The CYLD expression levels were determined by anti-FLAG immunoblotting. F, effects of CYLD-P904L mutant and MIB2 on TNFα-induced NF-κB activation in HEK293T cells. NF-κB promoter activities were measured in HEK293T cells transfected with either WT CYLD or the P904L mutant CYLD along with MIB2 in the presence or absence of TNFα. C and F, mean ± S.E. (n = 3). Statistical significance was assessed using one-way ANOVA. *, p < 0.001; **, p < 0.01.
**MIB2 enhances inflammation by degradation of CYLD**

is a key player in NF-κB signaling, we focused mainly on this signaling pathway, and showed that MIB2 negatively regulates CYLD function in the signaling pathway. These findings indicate the possibility that MIB2 is involved in other CYLD-related signaling pathways but this remains to be addressed.

The NF-κB signaling cascade is intimately involved in the inflammatory response (1, 2). In a previous report, no notable phenotype was observed in Mib2-knockout mice (45). Accordingly, we used the K/BxN STA model in the Mib2-deficient mice to explore the role of MIB2 in the inflammation response. As shown in Fig. 5, a biological role for MIB2 in the inflammatory response is suggested whereby it acts to induce the degradation of CYLD. Because CYLD is known to be a negative regulator of inflammation (25), its degradation through an MIB2-dependent mechanism suggests that a role for MIB2 in modulating the inflammatory response is not unreasonable. The next question that needs to be asked is “How is MIB2 expression regulated?”

TNFα treatment induces the formation of a TNFR signaling complex I (TNF-RSC) containing RIP1 and TRADD that are involved in NF-κB activation (46). In addition, a recent study has shown that LUBAC directly recruits CYLD to the TNF-RSC (47) and RIP1 recruits MIB2 to the TNF-RSC (48). These results suggest that both MIB2 and CYLD are involved in TNF-RSC. Actually they were co-immunoprecipitated with RIP1 (Fig. S7). Very recently, it was reported that RIP1 is ubiquitinated by MIB2 (48). Furthermore, RIP1 ubiquitination is decreased by CYLD (49). As this study shows, MIB2 degrades CYLD. Taken together, these studies suggest that MIB2 can regulate RIP1 ubiquitination by directly its E3 ubiquitin activity and CYLD degradation.

CYLD functions as a tumor suppressor in cylindromas and trichoepithelioma (17). Currently, nine missense mutations in CYLD have been found (50–58). However, the biological role of these missense mutations is unclear. Numerous cases of trichoepithelioma have been found to contain the CYLD<sup>P904L</sup> mutation (Fig. S6). In this study, we found that the CYLD<sup>P904L</sup>–MIB2 interaction was stronger than the interaction between WT CYLD and MIB2, and furthermore the CYLD<sup>P904L</sup> variant is efficiently degraded in a MIB2-dependent manner. MIB2 mainly interacts with D3 (287–589) region of CYLD (Fig. 1, E–G) and a position of Pro-904 seems not close to D3 region. To understand the effect of P904L mutation in CYLD on MIB2 interaction and MIB2-dependent ubiquitination, further analysis will be required. To the best of our knowledge, this is the first evidence of an alteration in biological function among the known missense mutations in CYLD. Our study also suggests that screening for stronger proteins interactions among the missense CYLD mutations may be a useful approach to understand the role of other missense CYLD mutations.

**Experimental procedures**

**Plasmids**

Full-length MIB2 and CS mutant [Mut (quadruple mutant C876S/C879S/C955S/C958S)] were cloned into pcDNA3.2/V5 dest or pEU-His vectors using the Gateway cloning system (Invitrogen). FLAG-tagged CYLD, FLAG-tagged NEMO, myc-tagged HOIP, and HA–His–tagged HOIL-1L in pcDNA3.2 vector were described previously (59). The CYLD plasmid was cloned into the GST-pEU vector using the Gateway cloning system. CYLD and MIB2 mutants were generated by site-directed mutagenesis using a PrimeSTAR Mutagenesis Basal Kit. FLAG- or biotin-labeled CYLD, DHFR, NEMO, or MIB2 for use in the AlphaScreen were generated using “split-primer PCR.” Lentiviruses-based GFP and MIB2 plasmids were generated using restriction enzyme digestion of a CS II-CMV-MCS-IRES2-Bsd vector. HA-tagged WT ubiquitin, Lys-48, and Lys-63 were a kind gift from Dr. Atsuo T. Sasaki, Cincinnati, OH.

**Antibodies**

The following antibodies were used in this study: Rabbit polyclonal anti-CYLD (used at 1:1000 dilution), a specific anti-Lys-48–linked polyubiquitin chain antibody, a specific anti-Lys-48–linked polyubiquitin chain antibody, and anti-β-TRCP (all used at 1:1000 dilution) were from Cell Signaling Technology; anti-MIB2 (used at 1:1000 dilution) was from Bethyl Laboratories; anti-NEMO (used at 1:1000 dilution) was from Santa Cruz Biotechnology; mouse polyclonal anti-CYLD (used at 1:1000 dilution) and anti-FLAG M2 (used at 1:2000 dilution) were from Sigma; anti-V5 (used at 1:5000 dilution) was from Invitrogen; anti-tubulin (used at 1:10000 dilution) was from Sigma; and the rat polyclonal anti–HA-HRP conjugate (used at 1:4500 dilution) was from Roche.

**Cell lines**

HEK293T and HeLa cells were incubated at 37 °C and 5% CO<sub>2</sub> in DMEM (Nissui) supplemented with 10% FBS (Sigma), 2 mM l-glutamine (Gibco), and antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin) (Gibco). Lentiviruses expressing GFP or MIB2 were generated according to a standard transfection protocol. After transmission of the transgene, a pool of HeLa cells resistant to blasticidin S (10 μg/ml) (Invitrogen) was generated and used in subsequent experiments. HeLa cells constitutively expressing GFP or MIB2 were incubated at 37 °C and 5% CO<sub>2</sub> in DMEM supplemented with 10% FBS, 2 mM l-glutamine, and antibiotics (100 units/ml penicillin and 100 μg/ml streptomycin).

MEFs were isolated from E13.5 embryos and cultured in high-glucose DMEM, GlutaMax, pyruvate (Gibco) supplemented with 10% FBS, 1× MEM nonessential amino acids, 55 μM 2-mercaptoethanol (Gibco), and 1× antibiotic-antimycotic (Gibco) based on previous reports (60).

**In vitro binding assays using the AlphaScreen technology**

**In vitro** binding assays were performed as described previously using an AlphaScreen IgG (protein A) detection kit (Perkin Elmer) (29). Briefly, 10 μl of detection mixture containing 20 mM Tris-Cl, pH 7.5, 0.2 mM DTT, 5 mM MgCl<sub>2</sub>, 5 μg/ml anti-FLAG antibody (Sigma), 1 mg/ml BSA, 0.1 μl streptavidin-coated donor beads, and 0.1 μl anti-IgG acceptor beads were added to each well of a 384-well OptiPlate followed by incubation at 26 °C for 1 h. Luminescence was detected using the AlphaScreen detection program.
MIB2 enhances inflammation by degradation of CYLD

**Cell transfections, immunoprecipitation, and immunoblotting**

HEK293T and HeLa cells were transfected with various plasmids using the TransIT-LT1 transfection reagent (Mirus) according to the manufacturer’s protocol. HEK293T and HeLa cells were transfected with a control siRNA, or an siRNA against MIB2 or β-TRCP using Lipofectamine™ RNAi MAX (Thermo Fisher Scientific) according to the manufacturer’s protocol. For the phosphorylated NF-κB assay, cells were treated with TNFα (20 ng/ml). For immunoprecipitation, cells were lysed with lysis buffer (150 mM NaCl, 25 mM Tris-HCl, pH 7.5, 1 mM EDTA, and 1% Triton X-100) containing a proteasome inhibitor and phosphatase inhibitors. After 2 μg of the indicated antibodies were bound to either protein A or protein G Dynabeads (Thermo Fisher Scientific) for 30 min at room temperature, they were incubated with whole-cell lysates overnight at 4 °C. The immunocomplexes were washed three times with the wash buffer provided in the Dynabeads kit. Immunoblotting was carried out following standard protocols. Briefly, proteins in whole-cell lysates were separated by SDS-PAGE (SDS-PAGE) and transferred onto a PVDF membrane by semi-dry blotting. After blocking with 5% milk/TEA, the membrane was incubated with the appropriate primary antibodies followed by a horseradish peroxidase (HRP)-conjugated secondary antibody.

**Protein purification**

Purification of GST-tagged protein was carried using Protemist® DT II according to the manufacturer’s protocol (Cell-Free Sciences Co. Ltd). Crude GST-tagged recombinant protein (6 ml) produced by the cell-free reaction was precipitated with GSH Sepharose™ 4B (GE Healthcare). Recombinant proteins were eluted with Elution Buffer A containing 10 mM reduced GSH, 50 mM Tris-HCl pH 8.0 and 50 mM NaCl. Purification of His-tagged proteins was also carried out using Protemist® DT II. Crude His-tagged recombinant protein (6 ml) produced by the cell-free reaction was precipitated with Ni Sepharose (GE Healthcare). The recombinant proteins were eluted with elution Buffer B including 500 mM imidazole, 20 mM N-phosphosphate pH 7.5 and 300 mM NaCl.

**In vitro ubiquitination assay**

The in vitro ubiquitination assay was performed as described previously (61). The assay was carried out in a 20-μl reaction mixture containing 20 mM Tris-HCl, pH 7.5, 0.2 mM DTT, 5 mM MgCl₂, 10 μM zinc acetate, 3 mM ATP, 1 μg/ml BSA, 2.5 μM FLAG-tagged ubiquitin, 50 nM E1 (Boston Biochem), 300 nM MgCl₂, 10 μM MgCl₂, 10 μM zinc acetate, 3 mM ATP, 1 μg/ml BSA, 2.5 μM FLAG-tagged ubiquitin, 50 nM E1 (Boston Biochem), 300 nM UbchSb (Enzo Life Sciences), and 1 μl of purified recombinant CYLD and MIB2 for 3 h at 30 °C.

**MS analysis**

The MS analysis was performed as described previously (62). Briefly, HEK293T cells were transfected with the indicated FLAG-CYLD construct along with V5-tagged MIB2 and HA-Ub. Forty-eight h after transfection, the whole-cell lysate was immunoprecipitated using an anti-FLAG antibody. Proteins were eluted using a FLAG peptide (Sigma). The eluted proteins were reduced in 5 mM Tris (2-carboxy-ethyl) phosphine hydrochloride for 30 min at 50 °C, and alkylated with 10 mM methylmethanethiosulfonate. Following this, the alkylated proteins were digested overnight at 37 °C using 1 μg trypsin. Ubiquitinated proteins were enriched using the PTMScan ubiquitin remnant motif (K-e-GG) kit (5562, Cell Signaling Technology) prior to LC-MS/MS analysis. Desalted tryptic digests were analyzed by nanoLC (Easy-nLC 1000; Thermo Fisher Scientific) coupled to a Q Exactive Plus (Thermo Fisher Scientific). Proteome Discoverer 1.4 (Thermo Fisher Scientific) was used to generate peak lists and analyze data.

**RNA interference**

Negative control (siRNA NC) siRNA and siRNAs against MIB2 (siRNA #1, 5'-GAACCUGCGGUAAGCAAGCU-GGU-3'; siRNA #2, 5'-CCUCAGGGAGUGCCAAACAU-GAUU-3'), and β-TRCP (siRNA, 5'-GAACUAUAAAGGUAUG-GAAAtt-3') were purchased from Invitrogen.

The lentivirus-mediated RNAi analysis was performed as described previously (63). The following sequences were selected as RNAi targets: MIB2 (shRNA MIB2#1, 5'-GAT-CGGGAGGTGCCAAAATCGATGT'TTCAAGGAAACAT-CGATGT'TTGGCACCCTTCTTT-TTG-3', shRNA MIB2#2, 5'-GATCCCTAGCTGTGAGAAATCTTTTCAAGGA-GAAGATTTCTTCAAGGAAATTTCTCTCAGCGTACAGCTTTTGG-3'), no-target (LacZ) (shRNA NC, 5'-GACTACACAAATCATCACGCG-3'). After construction of the shRNA expression plasmids by insertion of the respective double strand oligonucleotides, the lentivirus particles were generated using a standard transfection protocol. HeLa cells infected with lentiviruses expressing shRNA NC, shRNA MIB2#1 or shRNA MIB2#2 were used 5 days later.

**Protein turnover analysis**

All the turnover analyses were carried out using HeLa cells. Cells were transfected with the indicated plasmids. The following days, cells were treated with 100 μg/ml cycloheximide (CHX) for the indicated times.

**Reporter assays using TNFα and LUBAC**

All reporter assays were performed using a Dual-Luciferase Assay Kit (Promega). Cells were transfected with the indicated plasmids including LUBAC and reporters together with the pRL-TK reporter. Twenty h after transfection, the cells were treated with TNFα (20 ng/ml).

**Quantitative RT-PCR**

Total cellular RNA was extracted from HeLa cells using a RNeasy mini kit (Qiagen) and was reverse transcribed using a Transcriptor First Strand cDNA Synthesis Kit (Roche). The following primer sets were designed using the Assay Design Center software (Roche): MIB2 (forward: 5'-CTTCCA-CCGAGACCGACCC-3', reverse: 5'-CTGAAAATCAGCGATTTC-3'); IL-8 (forward: 5'-GGGAGGAGCTGCAAGGAGCA-3', reverse: 5'-AGGATTTGTTACCACACAGC-3'); and IL-8 (forward: 5'-GAGCACACTCCATAAGGCACAAA-3', reverse: 5'-GAACAGCAGGAGAAGTCC-3').
**MIB2 enhances inflammation by degradation of CYLD**

5'-ATGGTTCTCTCCTGGTGT-3'). Gene expression was normalized to ACTB (Roche).

**Mib2 knockout mouse**

The *Mib2* knockout first mice (C57BL/6NTac-*Mib2*tm1latELICOMMOWT/IcsOri) were obtained from The European Mouse Mutant Archive (64) and the floxed mice were generated by crossing with *ACTB-FLPe* mice (The Jackson Laboratory). Then, systemic knockout mice were generated by crossing *Mib2* flox and *CMV-Cre* mice, kindly provided by Prof. P. Chambron (65). Heterozygous knockout mice (*Mib2*+/−) were mated, and WT littermates (*Mib2*2+/+) and homozygous knockout littermates (*Mib2*2−/−) were obtained and are referred to as WT and KO, respectively. All mice were housed in a specific pathogen–free facility under climate-controlled conditions with a 12-h light/dark cycle and were provided with water and a standard diet (MF, Oriental Yeast, Japan) *ad libitum*. Animal experiments were approved by the Animal Experiment Committee of Ehime University (approval number 37A1-1/16) and were performed in accordance with the Guidelines of Animal Experiments of Ehime University.

**K/BxN STA**

STA was induced by the transfer of sera obtained from arthritic K/BxN mice, which spontaneously develop arthritis. K/BxN mice were generated by the crossing of NOD mice (Japan SLC, Inc., Shizuoka, Japan) with KRN transgenic mice, kindly provided by Drs. C. Benoist and D. Mathis (Harvard Medical School, Boston, MA) (66). K/BxN serum was harvested, pooled, and stored at −80 °C.

Eight- to 12-week-old male mice were used for K/BxN STA (*n* = 7). For STA induction, 100 μl of serum was injected intraperitoneally (i.p.) into these mice on day 0 and day 2, respectively.

The severity of arthritis in the limb was scored daily from day 0 to day 10. Evaluation of arthritis severity was performed as described previously (36): 0 = no evidence of erythema and swelling; 1 = erythema and mild swelling confined to the tarsals or ankle joint; 2 = erythema and mild swelling extending from the ankle to the tarsals; 3 = erythema and moderate swelling extending from the ankle to metatarsal joints; 4 = erythema and severe swelling encompass the ankle, foot, and digits, or ankylosis of the limb. Paw thickness was measured daily with a digital caliper.

**Histological evaluation**

Mice were euthanized at 10 days after K/BxN STA, and the ankle joints were cut and fixed with 4% paraformaldehyde, followed by decalcification with 0.5 M EDTA-PBS. Following this, the samples were embedded with paraffin and sectioned into 5-μm thickness, which were stained with hematoxylin and eosin.

Histological score was evaluated in a sample-blind manner. The histological severity of arthritis was graded using a scale of 0 to 3 for each ankle sections, where 0 = noninflamed, 1 = mild, 2 = moderate, 3 = severe.

**Immunofluorescent staining**

Cells were fixed with 4% paraformaldehyde in PBS for 5 min at room temperature, and then permeabilized with 0.5% Triton X-100 in PBS for 5 min. After blocking with 5% calf serum in TBST for 1 h, cells were incubated with a primary antibody overnight at 4 °C. After washing with TBST, cells were incubated with the appropriate Alexa Fluor 488– and/or 555–conjugated secondary antibodies (Molecular Probes) for 1 h at room temperature. Nuclei were counterstained with 4,6-diamidino-2-phenylindole. After a final wash with TBST, coverslips were mounted with anti-fade. Fluorescence images were acquired with the LSM710 laser scanning confocal microscope (Carl Zeiss).

**Bioinformatics analysis**

CYLD sequence of the following 11 biological species were based on the NCBI GenBank™: *Homo sapiens* (NP_001035814.1), *Mus musculus* (NP_001121643.1), *Rattus norvegicus* (NP_001017380.1), *Bos taurus* (NP_001039882.1), *Xenopus tropicalis* (NP_001116960.1), *Macaca mulatta* (XP_014981594.1), *Canis lupus familiaris* (XP_005617624.1), *Pan troglodytes* (XP_016785309.1), *Gallus gallus* (XM_015293982.1), *Cricetulus griseus* (XP_016829680.1) and *Danio rerio* (XP_005169076.1). Multiple-sequence alignment and the sequence logos were performed using Clustal Omega (67) and WebLogo3 (68), respectively.

**Statistical analyses**

One-way analysis of variance (ANOVA) followed by a post hoc Tukey’s test was performed using KaleidaGraph software. Statistical significance was accepted at *p* < 0.05.

**Author contributions**—A. U., F. T., and T. S. conceptualization; A. U. software; A. U., F. T., and T. S. funding acquisition; A. U., Y. I., F. T., and T. S. validation; A. U., K. K., C. T., Y. Y., N. S., Y. M. H., and T. K. investigation; A. U., Y. I., F. T., and T. S. methodology; A. U., F. T., and T. S. writing-original draft; K. K., H. T., C. T., M. M., K. S., S. H., Y. I., F. T., and T. S. data curation; K. S., S. H., Y. I., F. T., and T. S. supervision; Y. I., F. T., and T. S. formal analysis; Y. I., F. T., and T. S. writing-review and editing; F. T. and T. S. project administration.

**Acknowledgments**—We thank the Applied Protein Research Laboratory of Ehime University, and Chie Furukawa for technical assistance. We gratefully acknowledge Dr. Atsuo Sasaki (Cincinnati, OH) for kindly providing HA-tagged ubiquitin WT, Lys-48, and Lys-63 plasmids. We thank Dr. Natsuki Matsushita (Ehime University Graduate School of Medicine) for kindly providing the CS II-CMV-GFP-IRES-Bsd-H1 vector. We also acknowledge RIKEN for kindly providing the CS II-CMV-MCS-IRES2-Bsd vector.

**References**

1. Hayden, M. S., and Ghosh, S. (2004) Signaling to NF-κB. *Genes Dev.* 18, 2195–2224 [CrossRef] [Medline]
2. Karin, M., and Greten, F. R. (2005) NF-κB: Linking inflammation and immunity to cancer development and progression. *Nat. Rev. Immunol.* 5, 749–759 [CrossRef] [Medline]
3. Bassères, D. S., and Baldwin, A. S. (2006) Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. *Oncogene* 25, 6817–6830 [CrossRef] [Medline]
4. Karin, M., Cao, Y., Greten, F. R., and Li, Z.-W. (2002) NF-κB in cancer: From innocent bystander to major culprit. Nat. Rev. Cancer 2, 301–310 CrossRef Medline

5. Luo, J.-L., Kamata, H., and Karin, M. (2005) IKK/NF-κB signaling: Balancing life and death—a new approach to cancer therapy. J. Clin. Invest. 115, 2625–2632 CrossRef Medline

6. Gribnenvik, S. I., Greten, F. R., and Karin, M. (2010) Immunity, inflammation, and cancer. Cell 140, 883–899 CrossRef Medline

7. Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovskiy-Peyst, E., Urieli-Shoval, S., Galun, E., and Ben-Neriah, Y. (2004) NF-κB function as a tumor promoter in inflammation-associated cancer. Nature 431, 461–466 CrossRef Medline

8. Alkalay, I., Hatzubai, A., Orian, A., Ciechanover, A., and Ben-Neriah, Y. (1995) Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 92, 10599–10603 CrossRef Medline

9. Sethi, G., Sung, B., and Aggarwal, B. B. (2008) Nuclear factor-κB: A tumor suppressor deubiquitinatase regulating life and death—a new approach to cancer therapy. Oncotarget 5, 12126–12140 CrossRef Medline

10. Alkalay, I., Yaron, A., Hatzubai, A., Orian, A., Ciechanover, A., and Ben-Neriah, Y. (1995) Stimulation-dependent IκBα phosphorylation marks the NF-κB inhibitor for degradation via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. U.S.A. 92, 10599–10603 CrossRef Medline

11. Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998) Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 143, 1883–1898 CrossRef Medline

12. Pickart, C. M. (2001) Mechanisms underlying ubiquitination. Annu. Rev. Cell Dev. Biochem. 79, 425–479 CrossRef Medline

13. Kerscher, O., Felberbaum, R., and Hochstrasser, M. (2006) Modification of proteins by ubiquitin and ubiquitin-like proteins. Annu. Rev. Cell Dev. Biochem. 22, 159–180 CrossRef Medline

14. Pickart, C. M. (2001) Mechanisms underlying ubiquitination. Annu. Rev. Cell Dev. Biochem. 79, 425–479 CrossRef Medline

15. Wolf, S., Wei, D., and Green, D. R. (2009) The functional inventory of deubiquitinating enzymes. Cell 137, 773–786 CrossRef Medline

16. Young, A. L., Kellermayer, R., Szigeti, R., Tézsás, A., Azmi, S., and Celebi, J. T. (2006) CYLD mutations underlie Brooke-Spiegler syndrome, familial cylindromatosis, and multiple familial trichoepithelioma syndromes. Clin. Genet. 70, 246–249 CrossRef Medline

17. Massoumi, R., Kuphal, S., Hellerbrand, C., Hasa, B., Wild, P., Sprüss, T., Pfeifer, A., Fissler, R., and Bosserhoff, A. K. (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med. 206, 221–232 CrossRef Medline

18.igator, S. I., Greten, F. R., and Karin, M. (2010) Immunity, inflammation, and cancer. Cell 140, 883–899 CrossRef Medline

19. Johnston, J. A., Ward, C. L., and Kopito, R. R. (1998) Aggresomes: A cellular response to misfolded proteins. J. Cell Biol. 143, 1883–1898 CrossRef Medline

20. Nijman, S. M. B., Luna-Vargas, M. P. A., Velds, A., Brummelkamp, T. R., Dirac, A. M. G., Sixma, T. K., and Bernards, R. (2005) A genomic and functional inventory of deubiquitinating enzymes. Cell 123, 773–786 CrossRef Medline

21. Trompouki, E., Hatzivassiliou, E., Tsichritzis, T., Farmer, H., Ashworth, A., and Mosialos, G. (2003) CYLD is a deubiquitinating enzyme that neg-atively regulates NF-κB activation by TNFR family members. Nature 424, 793–796 CrossRef Medline

22. Massoumi, R., Kuphal, S., Hellerbrand, C., Hasa, B., Wild, P., Sprüss, T., Pfeifer, A., Fissler, R., and Bosserhoff, A. K. (2009) Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J. Exp. Med. 206, 221–232 CrossRef Medline

23. Taktakis, N., Adamou, A., Pappas, Z., Lyberatos, G., and Dranitsaris, G. (2008) Inflammation and cancer: From innocent bystander to major culprit. Nat. Rev. Cancer 8, 919–920 CrossRef Medline

24. Taktakis, N., Adamou, A., Pappas, Z., Lyberatos, G., and Dranitsaris, G. (2008) Inflammation and cancer: From innocent bystander to major culprit. Nat. Rev. Cancer 8, 919–920 CrossRef Medline

25. Taktakis, N., Adamou, A., Pappas, Z., Lyberatos, G., and Dranitsaris, G. (2008) Inflammation and cancer: From innocent bystander to major culprit. Nat. Rev. Cancer 8, 919–920 CrossRef Medline
MIB2 enhances inflammation by degradation of CYLD

44. Ye, J. S., Kim, N., Lee, K. J., Nam, Y. P., Lee, U., and Joo, C. H. (2014) Lysine 63-linked TANK-binding kinase 1 ubiquitination by mindbomb E3 ubiquitin protein ligase 2 is mediated by the mitochondrial antiviral signaling protein. J. Virol. 88, 12765–12776 CrossRef Medline

45. Koo, B.-K., Yoon, M.-J., Yoon, K.-J., Im, S.-K., Kim, Y.-Y., Kim, C.-H., Suh, P.-G., Jan, Y.-N., and Kong, Y.-Y. (2007) An obligatory role of mind bomb-1 in notch signaling of mammalian development. PLoS One 2, e1221 CrossRef Medline

46. Zinngrebe, J., Montinaro, A., Peltzer, N., and Walczak, H. (2014) Ubiquitin in the immune system. EMBO Rep. 15, 28 – 45 CrossRef Medline

47. Draber, P., Kupka, S., Reichert, M., Draberova, H., Lafont, E., de Miguel, D., Spilgies, L., Surinova, S., Taraborrelli, L., Hartwig, T., Rieser, E., Martino, L., Rittinger, K., and Walczak, H. (2015) IUBAC-recruited CYLD and A20 regulate gene activation and cell death by exerting opposing effects on linear ubiquitin in signaling complexes. Cell Rep. 13, 2258 – 2272 CrossRef Medline

48. Feltham, R., Jamal, K., Tenev, T., Liccardi, G., Jaco, I., Domingues, C. M., Vazmitel, M., Spagnolo, D., D., Elliott, P. R., Glatter, T., Qiao, Q., Thompson, A. J., Nesvizhskii, A., H., Schmidt, A., Komander, D., Wu, H., Martin, S., and Meier, P. (2018) Mind bomb regulates cell death during TNF signaling by suppressing RIPK1’s cytotoxic potential. Cell Rep. 23, 470 – 484 CrossRef Medline

49. Moquin, D. M., McCuaide, T., and Chan, F. K.-M. (2013) CYLD deubiquitinates RIP1 in the TNFα-induced necrosose to facilitate kinase activation and programmed necrosis. PLoS One 8, e67841 CrossRef Medline

50. Zuo, Y.-G., Xu, Y., Wang, B., Liu, Y.-H., Qu, T., Fang, K., and Ho, M. G. (2007) A novel mutation of CYLD in a Chinese family with multiple familial trichoepithelioma and no CYLD protein expression in the tumor tissue. Br. J. Dermatol. 157, 818 – 821 CrossRef Medline

51. Kazakov, D. V., Zelger, B., Rutten, A., Vazmitel, M., Spagnozzi, D. V., Kacerovska, D., Vanecrek, T., Grossmann, P., Sima, R., Grayson, W., Calone, E., Koren, J., Mukensnabl, P., Danis, D., and Michal, M. (2009) Morphologic diversity of malignant neoplasms arising in preexisting spiradenoma, cylindroma, and spiradenocylindroma based on the study of 24 cases, sporadic or occurring in the setting of Brooke-Spiegler syndrome: Report of 10 patients from 8 families with novel germ-line mutations: evidence of diverse somatic mutations in the same patient regardless of tumor type. Arch. Dermatol. Res. 302, 67 – 70 CrossRef Medline

52. España, A., García-Amigot, F., Aguado, L., and García-Foncillas, J. (2007) A novel missense mutation in the CYLD gene in a Spanish family with multiple familial trichoepithelioma. Arch. Dermatol. Res. 143, 1209 – 1210 CrossRef Medline

53. Lv, H. L., Huang, Y. J., Zhou, D., Du, Y. F., Zhao, X. Y., Liang, Y. H., Quan, C., Zhang, H., Zhou, F. S., Gao, M., Zhou, L., Yang, S., and Zhang, X. J. (2008) A novel missense mutation of CYLD gene in a Chinese family with multiple familial trichoepithelioma. J. Dermatol. Sci. 50, 143 – 146 CrossRef Medline

54. Zheng, G., Hu, L., Huang, W., Chen, K., Zhang, X., Yang, S., Sun, J., Jiang, Y., Luo, G., and Kong, X. (2004) CYLD mutation causes multiple familial trichoepithelioma in three Chinese families. Hum. Mutat. 23, 400 CrossRef Medline

55. Tokunaga, F., Nishimasu, H., Ishitani, R., Goto, E., Noguchi, T., Mio, K., Kamei, K., Ma, A., Iwai, K., and Nureki, O. (2012) Specific recognition of linear polyubiquitin by A20 zinc finger 7 is involved in NF-κB regulation. EMBO J. 31, 3856 – 3870 CrossRef Medline

56. Hyun, T. S., Li, L., Oravec–Wilson, K. I., Bradley, S. V., Provoit, M. M., Munaco, A. J., Mizukami, I. F., Sun, H., and Ross, T. S. (2004) Hip1-related mutant mice grow and develop normally but have accelerated spinal abnormalities and dwarfism in the absence of HIP1. Mol. Cell. Biol. 24, 4329 – 4340 CrossRef Medline

57. Takahashi, H., Nozawa, A., Seki, M., Shinozaki, K., Endo, Y., and Sawasaki, T. (2009) A simple and high-sensitivity method for analysis of ubiquitination and polyubiquitination based on wheat cell-free protein synthesis. BMC Plant Biol. 9, 39 CrossRef Medline

58. Yoshida, Y., Sasaki, Y., Murakami, A., Kawasaki, J., Tsuchiya, H., Yoshitake, M., Shindo, M., and Tanaka, K. (2015) A comprehensive method for detecting ubiquitinated substrates using TR-TUBE. Proc. Natl. Acad. Sci. U.S.A. 112, 4630 – 4635 CrossRef Medline

59. Shimizu, K., Uematsu, I., Imai, Y., and Sawasaki, T. (2014) Pctaire1/Cdk16 promotes skeletal myogenesis by inducing myoblast migration and fusion. FEBS Lett. 588, 3030 – 3037 CrossRef Medline

60. Skarnes, W. C., Rosen, B., West, A. P., Koutsourakis, M., Bushell, W., Iyer, V., Mujica, A. O., Thomas, M., Harrow, J., Cox, T., Jackson, D., Severin, J., Biggs, P., Fu, J., Nefedov, M., de Jong, P. J., Stewart, A. F., and Bradley, A. (2011) A conditional knockout resource for the genome-wide study of mouse gene function. Nature 474, 337 – 342 CrossRef Medline

61. Dupé, V., Davenne, D., Brocard, J., Dole, P., Mark, M., Dierich, A., Chambon, P., and Rijli, F. M. (1997) In vivo functional analysis of Hoxa-1 3’ retinoic acid response element (3’RARE). Development 124, 399 – 410 Medline

62. Kouskoff, V., Korganova, A.-S., Duchattele, V., Degott, C., Benoist, C., and Mathis, D. (1996) Organ-specific disease provoked by systemic autoimmunity. Cell 87, 811 – 822 CrossRef Medline

63. Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., Lopez, R., Maca, H., Remmert, M., Soding, J., Thompson, J. D., and Higgins, D. G. (2011) Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 CrossRef Medline

64. Crooks, G. E., Hon, G., Chandonia, J.-M., and Brenner, S. E. (2004) WebLogo: A sequence logo generator. Genome Res. 14, 1188 – 1190 CrossRef Medline